Drug interactions
Bosutinib + Ertugliflozin-sitagliptin
Severity: Minor
Bosutinib and Ertugliflozin-sitagliptin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Bosutinib inhibits P-glycoprotein and may raise sitagliptin concentrations. Because sitagliptin has a wide safety margin, clinically important effects are unlikely.
What this interaction means in plain words
Bosutinib and Ertugliflozin-sitagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Bosutinib belongs to Oncology; Ertugliflozin-sitagliptin belongs to Endocrine.
Why it happens
Inhibition of P-glycoprotein efflux of sitagliptin by bosutinib.
What to do
No dose adjustment is usually required. Monitor glycemic control and tolerability.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bosutinib and Ertugliflozin-sitagliptin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ertugliflozin-sitagliptin
Other interactions of Bosutinib
- Amiodarone + Bosutinib Major
- Apalutamide + Bosutinib Major
- Aprepitant + Bosutinib Major
- Bosentan + Bosutinib Major
- Bosutinib + Carbamazepine Major
- Bosutinib + Chlorpromazine Major
Frequently asked questions
Can I take Bosutinib with Ertugliflozin-sitagliptin?
MediHelp rates the interaction as minor. Bosutinib and Ertugliflozin-sitagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Bosutinib inhibits P-glycoprotein and may raise sitagliptin concentrations. Because sitagliptin has a wide safety margin, clinically important effects are unlikely.
How serious is the interaction between Bosutinib and Ertugliflozin-sitagliptin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is usually required. Monitor glycemic control and tolerability.
What other medicines interact with Ertugliflozin-sitagliptin?
MediHelp also lists interactions of Ertugliflozin-sitagliptin with, for example, Albiglutide, Aripiprazole, Asenapine. The full list is on the Ertugliflozin-sitagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
